CDH19 Antibody

What is CDH19 and what is its biological function?

CDH19 is a member of the cadherin superfamily of cell adhesion proteins. In normal physiology, cadherins play essential roles in maintaining tissue architecture and regulating cellular behavior through calcium-dependent cell-cell adhesion. CDH19 specifically belongs to the type II classical cadherin subfamily and has been implicated in cellular communication and tissue integrity maintenance. Research shows that CDH19 expression varies significantly across tissue types, with notable expression patterns in neural tissues and epithelial cells. In pathological contexts, particularly in cancer, CDH19 appears to function as a tumor suppressor in certain cancer types, including cervical carcinoma, where its downregulation correlates with disease progression .

What are the key considerations when selecting CDH19 antibodies for research?

When selecting CDH19 antibodies for research applications, several critical factors should be considered:

• Target specificity: Ensure the antibody specifically recognizes CDH19 and not other cadherin family members. This is particularly important given the structural similarities within the cadherin family.

• Application compatibility: Different experimental techniques require antibodies with specific characteristics. For example, some antibodies work well for western blotting but fail in immunohistochemistry applications .

• Clonality: Consider whether monoclonal or polyclonal antibodies are more suitable for your specific research question. Monoclonal antibodies offer high specificity for a single epitope, while polyclonal antibodies may provide stronger signals by binding multiple epitopes.

• Epitope location: Antibodies targeting different regions of CDH19 (extracellular domain, intracellular domain) may yield different results. For instance, antibodies directed against the extracellular domain peptides have shown better recognition of appropriate-sized proteins in western blotting compared to those targeting other regions .

• Validation evidence: Look for antibodies that have been validated in multiple applications and cell/tissue types relevant to your research.

Research has shown that antibodies generated against full-length CDH19 protein often perform better than those raised against small peptides, particularly for immunohistochemical applications in complex tissues .

How do expression patterns of CDH19 differ between normal and cancerous tissues?

CDH19 expression demonstrates significant variation between normal and cancerous tissues, making it a potential biomarker for certain malignancies. In gynecological cancers, particularly cervical carcinoma, CDH19 shows notable expression patterns:

In a study examining 20 pairs of cervical carcinoma and adjacent non-cancerous tissues, significant downregulation of CDH19 was observed across all tumor samples, reinforcing its potential role as a tumor suppressor in this cancer type .

How does CDH19 expression correlate with clinical outcomes in cancer patients?

CDH19 expression has shown significant correlations with clinical outcomes in cancer patients, particularly in cervical carcinoma:

The evidence suggests that monitoring CDH19 expression levels could provide clinically relevant information for determining patient prognosis and potentially guiding treatment decisions in cervical carcinoma.

What signaling pathways does CDH19 interact with during cancer development?

CDH19 has been found to interact with several critical signaling pathways involved in cancer progression, providing insight into its tumor-suppressive functions:

• AKT/NF-κB pathway: In cervical carcinoma, CDH19 overexpression significantly inhibits the activation of both AKT and NF-κB signaling pathways, which are crucial regulators of cell proliferation, survival, and inflammation .

• Crosstalk with proliferation markers: Analysis of public cancer databases has revealed a significant negative correlation between CDH19 expression and the proliferation marker Ki-67 in cervical carcinoma tissues, suggesting CDH19 may suppress tumor cell proliferation .

• Potential interactions with extracellular matrix components: In breast cancer research, CDH19 has been shown to interact with extracellular matrix proteins like laminin-511, which can activate the AKT signaling pathway and influence tumor growth .

• HPV-mediated pathways: Given that Human Papillomavirus (HPV) is the primary cause of cervical carcinoma and is known to activate the AKT/NF-κB pathway, CDH19's inhibitory effect on this pathway suggests it may counteract HPV-driven oncogenic processes .

These interactions position CDH19 as a potential regulatory node in cancer signaling networks, making it an attractive target for further investigation in cancer biology and potential therapeutic development.

What experimental models are most effective for studying CDH19 function in cancer?

Several experimental models have proven effective for investigating CDH19 function in cancer research:

• Cell line models: Established cervical carcinoma cell lines like CaSki and C-33A have been successfully used for CDH19 overexpression studies to assess its effects on cell proliferation and signaling pathway activation .

• Xenograft mouse models: In vivo models using immunodeficient mice implanted with CDH19-overexpressing cervical carcinoma cells have demonstrated reduced tumor growth rates, validating in vitro findings .

• Database analysis tools: Computational analysis using public cancer databases such as GEPIA (Gene Expression Profiling Interactive Analysis) and Kaplan-Meier plotter provides valuable insights into clinical correlations and expression patterns across large patient cohorts .

• Prostate cancer cell lines: For studying CDH19 in prostate cancer, cell lines like 22Rv1 that contain increased copy numbers of chromosome regions containing CDH7 (proximal to CDH19) have been utilized for immunohistochemical validation of antibodies .

When selecting an experimental model, researchers should consider the specific cancer type of interest, the research question being addressed, and the availability of appropriate controls for meaningful data interpretation.

What are the optimal protocols for CDH19 antibody validation?

Proper validation of CDH19 antibodies is crucial for generating reliable research data. The following comprehensive validation approach is recommended:

• Western blot validation:

  • Use bacterially-expressed CDH19 fusion protein as a positive control

  • Include both CDH19-positive and CDH19-negative cell lines as controls

  • Verify antibody specificity by observing bands of appropriate molecular weight (~120 kDa)

  • Compare multiple antibody clones to identify those with highest specificity

• Immunohistochemistry validation:

  • Test antibodies on cell lines with known CDH19 expression (e.g., 22Rv1 for prostate studies)

  • Include appropriate negative controls (primary antibody omission, isotype controls)

  • Optimize fixation and antigen retrieval methods for your specific tissue type

  • Compare staining patterns with mRNA expression data when possible

• Cross-reactivity assessment:

  • Test antibody against other cadherin family members, particularly closely related type II cadherins

  • Consider using CRISPR/Cas9 CDH19 knockout cell lines as definitive negative controls

• Batch consistency testing:

  • When possible, test multiple lots of the same antibody to ensure consistent performance

  • Maintain detailed records of antibody performance across different experimental conditions

According to research experience, hybridoma-derived monoclonal antibodies often provide more consistent results than those raised against small peptides, particularly for immunohistochemical applications .

What are the challenges in developing effective CDH19 antibodies for different applications?

Developing effective CDH19 antibodies presents several significant challenges that researchers should be aware of:

• Application-specific performance: Antibodies that perform well in one application may not function effectively in others. For example, among 29 monoclonal antibodies tested against CDH19, only 4 were found suitable for western blotting and 3 for immunohistochemistry, with just 1 antibody (20CIIA) working effectively in both applications .

• Epitope accessibility issues: Different experimental conditions can affect epitope accessibility. Antibodies directed against extracellular domain peptides may recognize proteins effectively in western blotting but fail in immunohistochemistry due to epitope masking during tissue fixation .

• Purification requirements: Many antibodies require extensive purification before they can be used effectively in certain applications. Initial antisera may need multiple purification steps before achieving suitable specificity for immunohistochemical analysis .

• Tissue-specific optimization needs: Antibodies that work well on one tissue type may perform poorly on others. For example, antibodies that were effective on brain tissue required further optimization for use on prostate tissue .

• Cross-reactivity concerns: Due to structural similarities among cadherin family members, ensuring specificity against CDH19 without cross-reactivity to other cadherins remains challenging.

The table below summarizes findings from a study evaluating multiple anti-CDH19 monoclonal antibodies for western blotting and immunohistochemistry applications:

This data highlights the difficulty in developing antibodies that perform consistently across different experimental techniques .

How should samples be prepared for CDH19 immunohistochemistry?

Optimal sample preparation for CDH19 immunohistochemistry requires careful attention to several critical factors:

• Fixation protocol:

  • Use 10% neutral-buffered formalin for 24-48 hours at room temperature

  • Avoid overfixation, which can mask CDH19 epitopes

  • For frozen sections, fix briefly (10-15 minutes) with 4% paraformaldehyde after sectioning

• Antigen retrieval methods:

  • Heat-induced epitope retrieval using citrate buffer (pH 6.0) or EDTA buffer (pH 9.0)

  • Optimize retrieval time (typically 15-30 minutes) and temperature (95-100°C)

  • Allow slides to cool slowly to room temperature after retrieval

• Blocking procedures:

  • Block endogenous peroxidase activity with 3% hydrogen peroxide

  • Use 5-10% normal serum from the species of secondary antibody origin

  • Include protein blocking step (e.g., 1% BSA) to reduce background staining

• Antibody dilution and incubation:

  • Determine optimal antibody dilution through titration experiments

  • Incubate primary antibody overnight at 4°C for maximum sensitivity

  • Use appropriate positive control tissues with known CDH19 expression

• Detection system selection:

  • For low-abundance proteins like CDH19, consider using amplification systems

  • Polymer-based detection systems often provide better signal-to-noise ratio

  • Chromogenic vs. fluorescent detection should be selected based on research needs

Research has shown that monoclonal antibodies like 20CIIA and 11D9 have demonstrated effectiveness for CDH19 immunohistochemistry in prostate cancer cell lines . When working with paraffin-embedded tissues, full-length protein-derived antibodies generally perform better than those raised against small peptides .

How can I troubleshoot false negatives in CDH19 antibody experiments?

False negatives can significantly compromise research results when working with CDH19 antibodies. Here are systematic approaches to address this common problem:

• Antibody validation issues:

  • Verify antibody functionality using positive control lysates or tissues

  • Consider testing multiple CDH19 antibody clones targeting different epitopes

  • Review antibody validation data from the manufacturer or published literature

  • Check if the antibody has been specifically validated for your application of interest

• Epitope masking problems:

  • Try alternative antigen retrieval methods (citrate vs. EDTA buffers, pH variations)

  • Extend antigen retrieval time or adjust temperature conditions

  • Consider using alternative fixation protocols that better preserve CDH19 epitopes

  • For western blotting, try reducing sample boiling time or using different detergents

• Sensitivity limitations:

  • Implement signal amplification steps (e.g., tyramide signal amplification)

  • Increase primary antibody concentration or extend incubation time

  • Switch to more sensitive detection systems (e.g., polymer-based detection)

  • Use fresh antibody aliquots to avoid potential degradation issues

• Sample preparation concerns:

  • Ensure samples were properly collected, fixed, and stored

  • Check for potential interfering substances in your buffer systems

  • For cell lines, verify CDH19 expression at the mRNA level using RT-PCR

• Technical optimization:

  • Adjust blocking conditions to improve antibody accessibility

  • Optimize washing steps to remove background while preserving specific signals

  • Consider automated staining platforms for more consistent results

Research has demonstrated that even among carefully developed monoclonal antibodies, only a small percentage (approximately 14% in one study) showed efficacy in immunohistochemical applications for CDH19 detection .

What controls should be included when working with CDH19 antibodies?

Proper controls are essential for ensuring reliability and interpretability of CDH19 antibody experiments:

• Positive controls:

  • Cell lines with verified CDH19 expression (e.g., certain prostate cancer cell lines like 22Rv1)

  • Tissues known to express CDH19 (e.g., specific neural tissues)

  • Recombinant CDH19 protein or CDH19-transfected cells

  • Bacterially-expressed CDH19 fusion protein lysates for western blotting

• Negative controls:

  • Cell lines with confirmed absence of CDH19 expression

  • CDH19 knockout cells generated via CRISPR/Cas9 or siRNA knockdown

  • Primary antibody omission controls to assess secondary antibody specificity

  • Isotype controls matched to the primary antibody's species and isotype

• Specificity controls:

  • Pre-adsorption controls using the immunizing peptide/protein

  • Testing the antibody against related cadherin family members

  • Comparing staining patterns with mRNA expression data from the same samples

  • Testing multiple antibody clones directed against different CDH19 epitopes

• Quantitative controls:

  • Standard curve using recombinant CDH19 protein for quantitative western blots

  • Housekeeping proteins (e.g., GAPDH) for western blot loading controls

  • Internal reference tissues with known CDH19 expression levels for IHC

  • Calibrated imaging parameters for consistent quantification

Effective experimental design should incorporate both technical and biological replicates to ensure robust and reproducible results when working with CDH19 antibodies.

How can CDH19 expression be quantified in experimental and clinical samples?

Accurate quantification of CDH19 expression is essential for both experimental research and potential clinical applications. Several methodologies are available, each with specific advantages:

• Western blot quantification:

  • Use digital image analysis software to measure band intensities

  • Always normalize to appropriate loading controls (e.g., GAPDH, β-actin)

  • Include a standard curve of recombinant CDH19 when absolute quantification is required

  • Report relative expression changes compared to control samples

• Immunohistochemistry quantification:

  • Implement standardized scoring systems (e.g., H-score, Allred score)

  • Consider digital pathology approaches with image analysis algorithms

  • Account for both staining intensity and percentage of positive cells

  • Use automated scanning systems for more objective quantification

• mRNA expression analysis:

  • Quantitative real-time PCR (qPCR) normalized to reference genes

  • Next-generation sequencing approaches for comprehensive profiling

  • Digital droplet PCR for absolute quantification of low-abundance transcripts

  • Validation of mRNA findings with protein-level analyses

• Flow cytometry:

  • Enables single-cell quantification of CDH19 expression

  • Allows simultaneous analysis of multiple parameters

  • Provides information about expression heterogeneity within populations

  • Requires effective antibodies specifically validated for flow cytometry

• Database-assisted quantification:

  • Utilize public cancer databases like GEPIA for large-scale expression analysis

  • Perform correlation analysis with other genes or clinical parameters

  • Compare expression across multiple cancer types and matched normal tissues

  • Use bioinformatic tools to normalize data across different platforms

For clinical applications, researchers have successfully used qPCR to quantify CDH19 expression in paired cervical carcinoma and adjacent normal tissues, demonstrating significant downregulation of CDH19 in tumor samples .

How can CDH19 be targeted for potential therapeutic applications?

CDH19's involvement in cancer progression, particularly its apparent tumor-suppressive role in cervical carcinoma, suggests several potential therapeutic strategies:

• Gene therapy approaches:

  • Viral vector-mediated CDH19 re-expression in tumors with downregulated CDH19

  • CRISPR activation systems to enhance endogenous CDH19 expression

  • mRNA delivery systems for temporary CDH19 restoration

• Pathway-based interventions:

  • Targeting the AKT/NF-κB pathway components that interact with CDH19

  • Developing small molecules that mimic CDH19's inhibitory effect on these pathways

  • Combination therapies addressing both CDH19 downregulation and pathway activation

• Immunotherapy strategies:

  • Developing CDH19-targeted antibody-drug conjugates

  • Engineering CAR-T cells to recognize cancer cells with aberrant CDH19 expression

  • Exploring the relationship between CDH19 expression and immune checkpoint inhibitor efficacy

• Prognostic and predictive applications:

  • Using CDH19 expression as a biomarker for patient stratification

  • Developing CDH19-based companion diagnostics for pathway inhibitors

  • Monitoring CDH19 levels during treatment to assess therapeutic efficacy

Research in xenograft mouse models has demonstrated that CDH19 overexpression significantly reduces the growth rate of cervical carcinoma tumors in vivo, suggesting that therapeutic approaches aimed at restoring CDH19 expression or function could have clinical relevance .

What are the conflicting findings in CDH19 research that require further investigation?

Despite growing interest in CDH19 research, several contradictory findings and knowledge gaps require further investigation:

These contradictions highlight the need for more comprehensive, mechanistic studies with larger, more diverse patient cohorts and standardized methodological approaches.

How does CDH19 interact with other cadherin family members in health and disease?

The interaction between CDH19 and other cadherin family members represents an important frontier in understanding cell adhesion biology in both normal physiology and disease states:

• Compensatory mechanisms:

  • When CDH19 is downregulated, other cadherins may compensate for its function

  • Comprehensive profiling of all cadherin family members in the same samples could reveal coordinated expression patterns

  • Understanding these compensatory networks may explain variable disease phenotypes

• Heterotypic interactions:

  • CDH19 may form heterotypic interactions with other cadherin subtypes

  • These interactions could modulate cell adhesion properties and downstream signaling

  • Research is needed to identify specific binding partners of CDH19 in different tissue contexts

• Genomic organization relevance:

  • CDH19 is genomically proximal to CDH7, and their expression may be co-regulated

  • Copy number alterations affecting multiple cadherin genes simultaneously could have synergistic effects

  • Integrated analysis of cadherin gene clusters could provide insights into their coordinated functions

• Signaling pathway crosstalk:

  • Different cadherins may activate distinct but overlapping signaling pathways

  • CDH19's regulation of AKT/NF-κB signaling may be influenced by other cadherin family members

  • Understanding this signaling network could reveal new therapeutic targets

• Evolutionary conservation patterns:

  • Comparative analysis of cadherin family members across species may reveal evolutionary adaptations

  • Conserved domains likely represent functionally critical regions for therapeutic targeting

  • Divergent regions may explain tissue-specific functions of different cadherins

Future research should focus on systematic approaches to map the "cadherin interactome" in specific tissue contexts, which could significantly advance our understanding of CDH19's role within this complex protein family.